Where Will Biogen Be in 5 Years?

There are two ways to imagine where Biogen (NASDAQ:BIIB) will be in five years. The optimistic scenario is that the biotech company is profitable, underpriced, and has a potential blockbuster drug, aducanumab, that if approved by the U.S. Food and Drug Administration (FDA), would allow the stock to take off. There's no cure for Alzheimer's, and there hasn't been a therapy approved to treat the disease since Namenda came along in 2003. A drug that could slow the disease would be huge for the Alzheimer's community (and for Biogen).